{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:42:02Z","timestamp":1793889722136,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ymthe.2020.02.016","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T19:43:14Z","timestamp":1582573394000},"page":"1251-1262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors"],"prefix":"10.1016","volume":"28","author":[{"given":"Caroline E.","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Rosewell Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngrock","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia D.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad C.","family":"Sandulache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Ittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm K.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.02.016_bib1","doi-asserted-by":"crossref","first-page":"14008","DOI":"10.1038\/mto.2014.8","article-title":"Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy","volume":"1","author":"Farzad","year":"2014","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2020.02.016_bib2","doi-asserted-by":"crossref","first-page":"27130","DOI":"10.1038\/srep27130","article-title":"T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies","volume":"6","author":"Velasquez","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.02.016_bib3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell Engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymthe.2020.02.016_bib4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T\u00a0cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2020.02.016_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2020.02.016_bib6","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib7","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib8","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T\u00a0cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.02.016_bib9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed oncolytic adenovirus-expressing PD-L1\u00a0mini-body enhances antitumor effects of chimeric antigen receptor T\u00a0cells in solid tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib10","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T\u00a0cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.02.016_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2015.00201","article-title":"Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer","volume":"6","author":"Misra","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib12","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0b013e32801403f4","article-title":"Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study","volume":"18","author":"Rupp","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ymthe.2020.02.016_bib14","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T\u00a0cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T\u00a0cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.02.016_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12032-015-0593-z","article-title":"Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts","volume":"32","author":"Hernandez","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1349-7006.1998.tb00493.x","article-title":"Expression of CD44 variants and its association with survival in pancreatic cancer","volume":"89","author":"Gotoda","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib18","doi-asserted-by":"crossref","first-page":"10233","DOI":"10.1158\/0008-5472.CAN-06-1464","article-title":"Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective","volume":"66","author":"G\u00f6tte","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1006\/gyno.2001.6406","article-title":"Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma","volume":"83","author":"Ayhan","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2020.02.016_bib22","doi-asserted-by":"crossref","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2020.02.016_bib23","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1038\/oncsis.2013.33","article-title":"A novel orthotopic mouse model of head and neck cancer and lymph node metastasis","volume":"2","author":"Masood","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ymthe.2020.02.016_bib24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrc.2017.92","article-title":"Preclinical mouse solid tumour models: status quo, challenges and perspectives","volume":"17","author":"Gengenbacher","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2020.02.016_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.02.016_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T\u00a0cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.02.016_bib27","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T\u00a0cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib29","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib30","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T\u00a0cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.02.016_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","article-title":"Immunology of adenoviral vectors in cancer therapy","volume":"15","author":"Shaw","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.02.016_bib32","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/jmv.25501","article-title":"Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma","volume":"91","author":"Kuryk","year":"2019","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib33","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","article-title":"Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade","volume":"25","author":"Chon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib34","doi-asserted-by":"crossref","first-page":"e1007209","DOI":"10.1371\/journal.ppat.1007209","article-title":"A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors","volume":"14","author":"Leoni","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2020.02.016_bib35","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.3389\/fimmu.2018.02734","article-title":"Signatures of T and B cell development, functional responses and PD-1 upregulation after HCMV latent infections and reactivations in Nod.Rag.gamma mice humanized with cord blood CD34+ cells","volume":"9","author":"Theobald","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib36","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2012.277","article-title":"Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in\u00a0vivo","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.02.016_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/hum.2009.096","article-title":"Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories","volume":"21","author":"Suzuki","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.02.016_bib38","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/hum.2012.003","article-title":"Capsid-modified adenoviral vectors for improved muscle-directed gene therapy","volume":"23","author":"Guse","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.02.016_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in\u00a0vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2020.02.016_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T\u00a0cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.02.016_bib41","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T\u00a0cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.02.016_bib42","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T\u00a0cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2020.02.016_bib43","doi-asserted-by":"crossref","first-page":"e57314","DOI":"10.1371\/journal.pone.0057314","article-title":"CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition","volume":"8","author":"Biddle","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2020.02.016_bib44","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/nprot.2009.171","article-title":"Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice","volume":"4","author":"Kim","year":"2009","journal-title":"Nat. Protoc."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620301027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620301027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:55:57Z","timestamp":1761501357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620301027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1525001620301027"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.02.016","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}